secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-282630
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara completes sale of tovinontrine and PDE9 assets to Cardurion for $34.75M upfront
--------------------------------------------------------------------------------

- Closed asset sale on Nov 10, 2022; received $34.75M upfront cash payment from Cardurion.
- Stockholders approved sale at special meeting on Nov 9: 18,366,825 for, 11,907 against, 47,876 abstain.
- Eligible for up to $10M proof-of-concept milestone and $50M regulatory/commercial milestones.
- Pro forma financial information to be filed within four business days of closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522282630/0001193125-22-282630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522282630/d752591d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-282630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer